Eli Lilly and Company released new data regarding the mechanism of action of basal insulin peglispro (BIL) at the 2014 American Diabetes Association Scientific Sessions.
When BIL was given to achieve complete suppression of glucose production, it showed less activity in peripheral tissues (eg, muscle and fat) than insulin glargine (Lantus; Sanofi). In a single-center crossover study, researchers measured both glucose disposal rate (GDR) and endogenous glucose production (EGP) rate to characterize peripheral vs. hepatic insulin action in 8 male subjects. Euglycemic clamps were performed every 8 hours with continuous intravenous infusions of BIL and insulin glargine.
The data supports the researchers’ hypothesis that BIL works more similarly to the body’s own insulin when compared to other exogenous insulins. BIL is currently being evaluated in Phase 3 clinical trials as a once-daily treatment for type 1 and type 2 diabetes.
For more information visit Lilly.com.